Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies

Critical Reviews in Oncology/Hematology

Volumn 75, Issue 1, 2010, Pages 2-14

  Sogno, Ilaria ^a   Venè, Roberta ^b   Ferrari, Nicoletta ^b   De Censi, Andrea ^c   Imperatori, Andrea ^d   Noonan, Douglas M ^a,d   Tosetti, Francesca ^b   Albini, Adriana ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Angiogenesis; Apoptosis; Chemoprevention; Fenretinide; Invasion; N (4 Hydroxyphenyl)retinamide

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FENRETINIDE; GAMMA INTERFERON; ISOTRETINOIN; RALOXIFENE; RETINOL DERIVATIVE; TAMOXIFEN; TOPOTECAN; VASCULOTROPIN RECEPTOR 2; VINCRISTINE; ANGIOGENESIS INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; GENE MUTATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KAPOSI SARCOMA; LOW DRUG DOSE; LUNG CANCER; LUNG SMALL CELL CANCER; NEUROBLASTOMA; NONHUMAN; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); NEOVASCULARIZATION, PATHOLOGIC; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; FENRETINIDE; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77953806733     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.10.007     Document Type: Review

References (134)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
3. Ebos J.M., Lee C.R., Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009, 15:5020-5025.
4. Albini A., Noonan D.M. Rescuing COX-2 inhibitors from the waste bin. J Natl Cancer Inst 2005, 97:859-860.
5. Albini A, Pennesi G, Donatelli F, Cammarota R, Flora SD, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and Cardio-Oncological Prevention, J Natl Cancer Inst; in press.
6. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008.
7. Albini A., Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007, 7:139-147.
8. Tosetti F., Ferrari N., De Flora S., Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002, 16:2-14.
9. Ferrari N., Morini M., Pfeffer U., Minghelli S., Noonan D.M., Albini A. Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res 2003, 9:6020-6029.
10. Ferrari N., Pfeffer U., Dell'Eva R., Ambrosini C., Noonan D.M., Albini A. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res 2005, 11:4610-4619.
11. Pienta K.J., Nguyen N.M., Lehr J.E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 1993, 53:224-226.
12. Tosetti F., Vene R., Arena G., et al. N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. Mol Pharmacol 2003, 63:565-573.
13. Sun S.Y., Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002, 41:41-55.
14. Wake K. Sternzellen in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 1971, 132:429-462.
15. Senoo H., Wake K. Suppression of experimental hepatic fibrosis by administration of vitamin A. Lab Invest 1985, 52:182-194.
16. Hixson E.J., Denine E.P. Comparative subacute toxicity of all-trans- and 13-cis-retinoic acid in Swiss mice. Toxicol Appl Pharmacol 1978, 44:29-40.
17. Sabichi A.L., Xu H., Fischer S., et al. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites. Clin Cancer Res 2003, 9:4606-4613.
18. Moon R.C., Thompson H.J., Becci P.J., et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979, 39:1339-1346.
19. Pollard M., Luckert P.H., Sporn M.B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991, 51:3610-3611.
20. Conaway C.C., Jiao D., Kelloff G.J., Steele V.E., Rivenson A., Chung F.L. Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett 1998, 124:85-93.
21. Formelli F., Cleris L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993, 53:5374-5376.
22. Orienti I., Zuccari G., Bergamante V., et al. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration. Biomacromolecules 2007, 8:3258-3262.
23. Okuda T., Kawakami S., Higuchi Y., et al. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. Int J Pharm 2009, 373:100-106.
24. Orienti I., Zuccari G., Carosio R., Montaldo P.G. Improvement of aqueous solubility of fenretinide and other hydrophobic anti-tumor drugs by complexation with amphiphilic dextrins. Drug Deliv 2009, 16:389-398.
25. Albini A., D'Agostini F., Giunciuglio D., Paglieri I., Balansky R., De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 1995, 61:121-129.
26. Cai T., Fassina G., Morini M., et al. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 1999, 79:1151-1159.
27. Albini A., Morini M., D'Agostini F., et al. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res 2001, 61:8171-8178.
28. De Flora S., D'Agostini F., Masiello L., Giunciuglio D., Albini A. Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer 1996, 67:842-848.
29. Sica A., Larghi P., Mancino A., et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008, 18:349-355.
30. Sozzani S., Rusnati M., Riboldi E., Mitola S., Presta M. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 2007, 28:385-392.
31. Villablanca E.J., Zhou D., Valentinis B., et al. Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol 2008, 84:871-879.
32. Zanardi S., Serrano D., Argusti A., Barile M., Puntoni M., Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 2006, 13:51-68.
33. Veronesi U., De Palo G., Marubini E., et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999, 91:1847-1856.
34. De Palo G., Mariani L., Camerini T., et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002, 86:24-27.
35. Formelli F., Meneghini E., Cavadini E., et al. Plasma retinol and prognosis of postmenopausal breast cancer patients. Cancer Epidemiol Biomarkers Prev 2009, 18:42-48.
36. Veronesi U., Mariani L., Decensi A., et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006, 17:1065-1071.
37. Rajaram S., Baylink D.J., Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18:801-831.
38. Decensi A., Veronesi U., Miceli R., et al. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 2003, 9:4722-4729.
39. Tu Y., Jerry D.J., Pazik B., Smith Schneider S. Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res 2005, 3:435-442.
40. Simeone A.M., Deng C.X., Kelloff G.J., Steele V.E., Johnson M.M., Tari A.M. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 2005, 26:1000-1007.
41. Turton J.A., Willars G.B., Haselden J.N., Ward S.J., Steele C.E., Hicks R.M. Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol 1992, 73:551-563.
42. Fontana J.A. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 1987, 55:136-144.
43. Ratko T.A., Detrisac C.J., Dinger N.M., Thomas C.F., Kelloff G.J., Moon R.C. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 1989, 49:4472-4476.
44. Cope M.B., Steele V.E., Lubet R.A., et al. Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention. Oncol Rep 2004, 11:465-469.
45. Anzano M.A., Byers S.W., Smith J.M., et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994, 54:4614-4617.
46. Anzano M.A., Peer C.W., Smith J.M., et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996, 88:123-125.
47. Guerrieri-Gonzaga A., Robertson C., Bonanni B., et al. Preliminary results on safety and activity of a randomized, double-blind, 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2006, 24:129-135.
48. Decensi A., Bonanni B., Baglietto L., et al. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res 2004, 10:4389-4397.
49. Decensi A., Robertson C., Guerrieri-Gonzaga A., et al. Randomized double-blind 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009, 27:3749-3756.
50. Garaventa A., Luksch R., Lo Piccolo M.S., et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003, 9:2032-2039.
51. Zou C.P., Kurie J.M., Lotan D., Zou C.C., Hong W.K., Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998, 4:1345-1355.
52. Kurie J.M., Lee J.S., Khuri F.R., et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000, 6:2973-2979.
53. Schneider B.J., Worden F.P., Gadgeel S.M., et al. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 2009.
54. Tosetti F., Noonan D.M., Albini A. Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. Int J Cancer 2009, 125:1997-2003.
55. Lovat P.E., Ranalli M., Corazzari M., et al. Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. J Cell Biochem 2003, 89:698-708.
56. Maurer B.J., Metelitsa L.S., Seeger R.C., Cabot M.C., Reynolds C.P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999, 91:1138-1146.
57. Raffaghello L., Pagnan G., Pastorino F., et al. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer 2003, 104:559-567.
58. Reynolds C.P., Lemons R.S. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001, 15:867-910.
59. Montaldo P.G., Pagnan G., Pastorino F., et al. N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. Int J Cancer 1999, 81:262-267.
60. Puduvalli V.K., Saito Y., Xu R., Kouraklis G.P., Levin V.A., Kyritsis A.P. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 1999, 5:2230-2235.
61. Puduvalli V.K., Li J.T., Chen L., McCutcheon I.E. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 2005, 65:1547-1553.
62. Dmitrovsky E. Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst 2004, 96:1264-1265.
63. Bu P., Wan Y.J. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer 2007, 7:236.
64. Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998, 90:597-605.
65. Hail N., Lotan R. Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J Biol Chem 2001, 276:45614-45621.
66. Sun S.Y., Li W., Yue P., Lippman S.M., Hong W.K., Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999, 59:2493-2498.
67. Suzuki S., Higuchi M., Proske R.J., Oridate N., Hong W.K., Lotan R. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 1999, 18:6380-6387.
68. Ulukaya E., Pirianov G., Kurt M.A., Wood E.J., Mehmet H. Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ 2003, 10:856-859.
69. Lovat P.E., Ranalli M., Annichiarrico-Petruzzelli M., et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res 2000, 260:50-60.
70. Cuperus R., Tytgat G.A., Leen R., et al. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. Int J Oncol 2008, 32:1011-1019.
71. Kadara H., Tahara E., Kim H.J., Lotan D., Myers J., Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res 2008, 68:4416-4423.
72. Kang M.H., Wan Z., Kang Y.H., Sposto R., Reynolds C.P. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008, 100:580-595.
73. Appierto V., Tiberio P., Villani M.G., Cavadini E., Formelli F. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009, 30:824-831.
74. Hill D.S., Martin S., Armstrong J.L., et al. Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma. Clin Cancer Res 2009, 15:1192-1198.
75. Pagnan G., Di Paolo D., Carosio R., et al. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res 2009, 15:1199-1209.
76. Kohno K. How transmembrane proteins sense endoplasmic reticulum stress. Antioxid Redox Signal 2007, 9:2295-2303.
77. Lai W.L., Wong N.S. The PERK/eIF2 alpha signaling pathway of unfolded protein response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells. Exp Cell Res 2008, 314:1667-1682.
78. DiPietrantonio A.M., Hsieh T.C., Juan G., Traganos F., Darzynkiewicz Z., Wu J.M. Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 2000, 60:4331-4335.
79. Batra S., Reynolds C.P., Maurer B.J. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 2004, 64:5415-5424.
80. Erdreich-Epstein A., Tran L.B., Bowman N.N., et al. Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 2002, 277:49531-49537.
81. Lovat P.E., Di Sano F., Corazzari M., et al. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004, 96:1288-1299.
82. O'Donnell P.H., Guo W.X., Reynolds C.P., Maurer B.J. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002, 16:902-910.
83. Wang H., Maurer B.J., Reynolds C.P., Cabot M.C. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001, 61:5102-5105.
84. Guilbault C., De Sanctis J.B., Wojewodka G., et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008, 38:47-56.
85. Guilbault C., Wojewodka G., Saeed Z., et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2009, 41:100-106.
86. Boya P., Morales M.C., Gonzalez-Polo R.A., et al. The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family. Oncogene 2003, 22:6220-6230.
87. Chen Y.R., Zhou G., Tan T.H. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Mol Pharmacol 1999, 56:1271-1279.
88. Appierto V., Villani M.G., Cavadini E., Lotan R., Vinson C., Formelli F. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ 2004, 11:270-279.
89. Lovat P.E., Oliverio S., Corazzari M., et al. Induction of GADD153 and Bak: novel molecular targets of fenretinide-induced apoptosis of neuroblastoma. Cancer Lett 2003, 197:157-163.
90. Cuello M., Coats A.O., Darko I., et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004, 11:527-541.
91. Vene R., Arena G., Poggi A., et al. Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications. Mol Cancer Ther 2007, 6:286-298.
92. Schroeder C.P., Kadara H., Lotan D., et al. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res 2006, 66:9762-9770.
93. Muller A., Nakagawa H., Rustgi A.K. Retinoic acid and N-(4-hydroxy-phenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Cancer Lett 1997, 113:95-101.
94. Lippman S.M., Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000, 130:479S-482S.
95. Kini A.R., Peterson L.A., Tallman M.S., Lingen M.W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001, 97:3919-3924.
96. Lingen M.W., Polverini P.J., Bouck N.P. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol 1996, 149:247-258.
97. Lingen M.W., Polverini P.J., Bouck N.P. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998, 58:5551-5558.
98. Iurlaro M., Benelli R., Masiello L., Rosso M., Santi L., Albini A. Beta Interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid. Eur J Cancer 1998, 34:570-576.
99. Pili R., Kruszewski M.P., Hager B.W., Lantz J., Carducci M.A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001, 61:1477-1485.
100. Ribatti D., Alessandri G., Baronio M., et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 2001, 94:314-321.
101. Ribatti D., Raffaghello L., Marimpietri D., et al. Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett 2003, 197:181-184.
102. Simile M.M., Pagnan G., Pastorino F., et al. Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis 2005, 26:417-427.
103. Majewski S., Marczak M., Szmurlo A., Jablonska S., Bollag W. Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 1995, 89:117-124.
104. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
105. Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 2003, 22:6589-6597.
106. Delafontaine P., Song Y.H., Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004, 24:435-444.
107. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002, 277:38205-38211.
108. Stoeltzing O., Liu W., Reinmuth N., et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003, 163:1001-1011.
109. Torrisi R., Parodi S., Fontana V., et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Int J Cancer 1998, 76:787-790.
110. Serrano D., Baglietto L., Johansson H., et al. Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer. Clin Cancer Res 2005, 11:2083-2088.
111. Favoni R.E., de Cupis A., Bruno S., et al. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer 1998, 77:2138-2147.
112. Erdreich-Epstein A., Shimada H., Groshen S., et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000, 60:712-721.
113. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
114. Lopez-Hernandez F.J., Ortiz M.A., Bayon Y., Piedrafita F.J. Reduced concentrations of serum enhance the antiproliferative activity of retinoid-related molecules and accelerate the onset of apoptosis. Biochem Pharmacol 2003, 65:2021-2030.
115. Piccirillo S.G., Reynolds B.A., Zanetti N., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
116. Hallahan A.R., Pritchard J.I., Chandraratna R.A., et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 2003, 9:1033-1038.
117. Qiu T., Grizzle W.E., Oelschlager D.K., Shen X., Cao X. Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1. EMBO J 2007, 26:346-357.
118. Kaplan R.N., Rafii S., Lyden D. Preparing the " soil": the premetastatic niche. Cancer Res 2006, 66:11089-11093.
119. Lotan R. Retinoids as modulators of tumor cells invasion and metastasis. Semin Cancer Biol 1991, 2:197-208.
120. Bollag W., Majewski S., Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia 1994, 8:1453-1457.
121. Shaker M.R., Yang G., Timme T.L., et al. Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis 2000, 18:429-438.
122. Pollard M., Luckert P.H. The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett 1991, 59:159-163.
123. Takahashi N., Tamagawa K., Shimizu K., Fukui T., Maitani Y. Effects on M5076-hepatic metastasis of retinoic acid and N-(4-hydroxyphenyl) retinamide, fenretinide entrapped in SG-liposomes. Biol Pharm Bull 2003, 26:1060-1063.
124. Kim J.H., Tanabe T., Chodak G.W., Rukstalis D.B. In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma. Anticancer Res 1995, 15:1429-1434.
125. Simeone A.M., Colella S., Krahe R., Johnson M.M., Mora E., Tari A.M. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis 2006, 27:568-577.
126. Um S.J., Lee S.Y., Kim E.J., et al. Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett 2001, 174:127-134.
127. Um S.J., Sin H.S., Han H.S., et al. Potent cytotoxic effects of novel retinamide derivatives in ovarian cancer cells. Biol Pharm Bull 2003, 26:1412-1417.
128. Golubkov V., Garcia A., Markland F.S. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res 2005, 25:249-253.
129. Shishodia S., Gutierrez A.M., Lotan R., Aggarwal B.B. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res 2005, 65:9555-9565.
130. Albini A., Tosetti F., Benelli R., Noonan D.M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res 2005, 65:10637-10641.
131. Vaccari M., Silingardi P., Argnani A., et al. In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res 2000, 20:3059-3066.
132. Webber M.M., Bello-DeOcampo D., Quader S., Deocampo N.D., Metcalfe W.S., Sharp R.M. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis 1999, 17:255-263.
133. Rozzo C., Chiesa V., Caridi G., Pagnan G., Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer 1997, 70:688-698.
134. Panigone S., Bergomas R., Fontanella E., et al. Up-regulation of prosaposin by the retinoid HPR and its effect on ceramide production and integrin receptors. FASEB J 2001, 15:1475-1477.